Alivus Life Sciences Limited (NSE:ALIVUS)
India · Delayed Price · Currency is INR 883.50
+22.00 (2.55%)
Jan 23, 2026, 3:29 PM IST
Alivus Life Sciences Revenue
Alivus Life Sciences had revenue of 6.73B INR in the quarter ending December 31, 2025, with 4.84% growth. This brings the company's revenue in the last twelve months to 25.12B, up 10.48% year-over-year. In the fiscal year ending March 31, 2025, Alivus Life Sciences had annual revenue of 23.87B with 4.54% growth.
Revenue (ttm)
25.12B
Revenue Growth
+10.48%
P/S Ratio
4.32
Revenue / Employee
11.40M
Employees
2,203
Market Cap
108.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 23.87B | 1.04B | 4.54% |
| Mar 31, 2024 | 22.83B | 1.22B | 5.64% |
| Mar 31, 2023 | 21.61B | 380.06M | 1.79% |
| Mar 31, 2022 | 21.23B | 2.38B | 12.63% |
| Mar 31, 2021 | 18.85B | 3.48B | 22.63% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Piramal Pharma | 89.36B |
| Alembic Pharmaceuticals | 70.83B |
| Gland Pharma | 58.01B |
| Strides Pharma Science | 46.85B |
| NATCO Pharma | 43.90B |
| Akums Drugs and Pharmaceuticals | 41.10B |
| Wockhardt | 30.07B |
| Eris Lifesciences | 29.86B |